Skip to main content

Pharmacodynamic Effects of Sulodexide on Profibrinolytic and Haemorrheological Patterns

Clinical Drug Investigation volume 10, pages 165–171 (1995)Cite this article

Summary

Twenty-four patients with vascular disorders, randomly divided into 3 dosage groups of 8 patients, were treated with a single oral dose of sulodexide (50, 100 or 200mg) and placebo. Tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI-1) activity and antigen, euglobulin lysis time, α2-antiplasmin, plasminogen, fibrinogen, blood and plasma viscosity, and whole blood filtration rate were determined before administration and over the following 24 hours. Sulodexide significantly increased t-PA activity linearly with the dose over the range of 50 to 200mg. At the same time, it also significantly decreased the concentration of PAI-1 linearly and proportionally with the dose. No clear effects were observed on the other monitored parameters, although euglobulin lysis time and plasma viscosity showed a tendency to decrease after the administration of sulodexide. These results justify the clinical activity of sulodexide. Indeed, the concomitant increase of t-PA and decrease of PAI-1 activity and antigen might increase the natural fibrinolytic activity with a physiological potentiation, without other adverse effects. The known activity of sulodexide in decreasing plasma viscosity during long term treatment is, however, not immediately explicable by the single-dose effects.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Caramelli L, Mirchioni R, Carini A. Effectiveness of short term sulodexide treatment on peripheral vascular disease — clinical manifestations. Eur Rev Med Pharmacol Sci 1988; 10: 55–8

    CAS  Google Scholar 

  2. Castelluccio A, Bologna E. Effect of sulodexide on blood viscosity in patients with peripheral vascular disease. Curr Med Res Opin 1991; 12: 325–31

    PubMed  Article  CAS  Google Scholar 

  3. Ciuffetti G, Mercuri M, Susta A, et al. Effects of 3-glycosaminoglycan sulphate on haemorheologic parameters in hyperlipidemic peripheral vascular disease (PVD) patients: a preliminary double-blind cross-over study. Angiology 1989; 40: 255–9

    PubMed  Article  CAS  Google Scholar 

  4. Cospite M, Milio G, Ferrara F, et al. Double-blind study of the pharmacological effects of sulodexide in patients with multiple atherosclerotic vascular diseases. Eur Rev Med Pharmacol Sci 1985; 7: 97–106

    Google Scholar 

  5. Crepaldi G, Fellin R, Calabro’ A, et al. Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use Atherosclerosis 1990; 81: 233–42

    CAS  Google Scholar 

  6. Degiglio V, Guida C. Prevention of vascular complications from immobility using sulodexide. Med Praxis 1990; 11: 1–8

    Google Scholar 

  7. Della Marchina M, Bellucci M, Palazzini E. Medium term oral sulodexide treatment in diabetic patients suffering from peripheral arterial obstructive disease: a double blind, placebo-controlled study. Prog Rep 1992; 4: 5–15

    Google Scholar 

  8. Liguori L, Saviano M, Lampugnani R, et al. Double-blind, double-dummy, randomised, clinical assessment of efficacy, tolerability and dose-effect relationship of oral sulodexide in obstructive peripheral arterial disorders. Adv Ther 1993; 10: 52–66

    Google Scholar 

  9. Luttichau U, Palazzini E. Pharmacological treatment of postphlebitic syndromes with sulodexide. Med Praxis 1992; 13; 1–8

    Google Scholar 

  10. Pisano L, Moronesi F, Falco F, et al. The use of sulodexide in the treatment of peripheral vasculopathy accompanying metabolic diseases. Thromb Res 1986; 41: 23–31

    PubMed  Article  CAS  Google Scholar 

  11. Saviano M, Maleti O, Liguori L, et al. Double-blind, double-dummy, randomised, multicentre clinical assessment of efficacy, tolerability and dose-effect relationship of sulodexide in chronic venous insufficiency. Curr Med Res Opin 1993; 13: 96–108

    PubMed  Article  CAS  Google Scholar 

  12. Verardi S, Ippoliti A, Ramundo A, et al. Medium term treatment of chronic venous insufficiency with oral sulodexide. Aggiorn Med Chir 1992; 11: 230–40

    Google Scholar 

  13. Andriuoli G, Mastacchi R, Barbanti M. Antithrombotic activity of a glycosaminoglycan (sulodexide) in rats. Thromb Res 1984; 34: 81–6

    PubMed  Article  CAS  Google Scholar 

  14. Barbanti M, Guizzardi S, Calanni F, et al. Antithrombotic and thrombolytic activity of sulodexide in rats. Int J Clin Lab Res 1992; 22: 179–84

    PubMed  Article  CAS  Google Scholar 

  15. Agrati AM, Mauro M, Savasta C, et al. A double-blind, crossover, placebo-controlled study of the profibrinolytic and antithrombotic effects of oral sulodexide. Adv Ther 1992; 9: 147–55

    Google Scholar 

  16. Crepaldi G, Rossi A, Coscetti G, et al. Sulodexide oral administration influences blood viscosity and fibrinolysis. Drugs Exp Clin Res 1992; 18: 189–95

    PubMed  CAS  Google Scholar 

  17. Fiore G, Baraldi A, Gambarotta C, et al. Inhibition of plasminogen activator inhibitor (PAI-1) by sulodexide in postthrombophlebitic patients. J Drug Devel 1991; 3: 173–8

    Google Scholar 

  18. Mannarino E, Pasqualini L, Ciuffetti G, et al. Effect of oral administration of sulodexide on fibrinolysis and plasma viscosity. Drug Invest 1992; 4: 346–50

    Article  CAS  Google Scholar 

  19. Mauro M, Ferraro G, Palmieri GC. Profibrinolytic and antithrombotic effects of sulodexide oral administration: a double-blind, cross-over, placebo-controlled study. Curr Ther Res 1992; 51: 342–50

    Google Scholar 

  20. Romano F, Platania M, Costa A, et al. The effect of sulodexide on blood viscosity in patients with peripheral vascular disease. Eur J Clin Res 1992; 3: 73–82

    Google Scholar 

  21. Condorelli M, Chiariello M, Dagianti M, et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol 1994; 23: 27–34

    PubMed  Article  CAS  Google Scholar 

  22. Von Kaulla KN, Schultz RL. Methods for the evaluation of human fibrinolysis. Am J Clin Pathol 1958; 29: 104

    Google Scholar 

  23. Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its ‘fast’ inhibitor in plasma. Clin Chem 1986; 32: 482–5

    PubMed  CAS  Google Scholar 

  24. Nilsson K, Rosen S, Friberger P. A new kit for the determination of tissue plasminogen activator and its inhibitor in blood. Fibrinolysis 1987; 1: 163

    CAS  Google Scholar 

  25. Verheijen JH, Mullart E, Chang GCT, et al. A simple sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982; 48: 266–9

    PubMed  CAS  Google Scholar 

  26. Declerck PJ, Alessi MC, Verteken M, et al. Measurement of plasminogen activator inhibitor 1 (PAI-1) in biological fluids with a murine monoclonal antibody based enzyme-linked immunosorbent assay. Blood 1988; 71: 220–5

    PubMed  CAS  Google Scholar 

  27. Juhan-Vague I, Alessi M, Fossat C, et al. Plasma determination of plasminogen activator inhibitor 1 antigen must be performed in blood collected on antiplatelet/anticoagulant mixture. Thromb Haemost 1987; 58: 1096

    PubMed  CAS  Google Scholar 

  28. Di Perri T, Forconi S, Di Lollo F, et al. Le sindromi da iperviscosità ematica. Fisiologia, patologia e clinica. In: Pozzi G, editor. ‘Atti 84° Congresso Società Italiana di Medicina Interna’. Rome: 1993: 74–92

    Google Scholar 

  29. Reid HL, Barnes AJ, Lock PJ, et al. A simple method for measuring erythrocyte deformability. J Clin Pathol 1976; 10: 855

    Article  Google Scholar 

  30. Forconi S, Guerrini M, Pieragalli D, et al. Rilievi metodologici sulla filtrazione del sangue intero nella valutazione della deformabilità eritrocitaria. Nota I: effetto della temperatura. Ric Clin Lab 1983; 13: 271–4

    PubMed  Google Scholar 

  31. Angleton P, Chandler WL, Chmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1). Circulation 1989; 79: 101

    PubMed  Article  CAS  Google Scholar 

  32. Kluft C, Jie AFH, Rijken DC, et al. Daytime fluctuation in blood of tissue-type plasminogen activator (t-PA) and its fast acting inhibitor (PAI-1). Thromb Haemost 1988; 59: 329

    PubMed  CAS  Google Scholar 

  33. Cospite M, Milio G, Ferrara F, et al. Haemodynamic effects of sulodexide in post-thrombophlebitic syndrome. Acta Ther 1992; 18: 149–61

    Google Scholar 

Download references

Author information

Affiliations

  1. Institute of Clinical Medicine, School of Medicine, University of Siena, Siena, Italy

    G. L. Messa, G. La Placa, L. Puccetti, A. Acciavatti, T. Provvedi & T. Di Perri

  2. Alfa Wassermann SpA, Bologna, Italy

    E. Palazzini

Authors
  1. G. L. Messa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. La Placa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Puccetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Acciavatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T. Provvedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Palazzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Di Perri
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Messa, G.L., La Placa, G., Puccetti, L. et al. Pharmacodynamic Effects of Sulodexide on Profibrinolytic and Haemorrheological Patterns. Clin. Drug Invest. 10, 165–171 (1995). https://doi.org/10.2165/00044011-199510030-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-199510030-00005

Keywords

  • Plasminogen Activator
  • Single Oral Dose
  • Plasminogen Activator Inhibitor
  • Drug Invest
  • Pharmacodynamic Effect